ArticlePloS one2012
Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.World journal of gastroenterology · 2014Pooled it
- Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.World journal of gastroenterology · 2013Pooled it
- The role of gut microbiota and its metabolites in preventing oncogenesis.Frontiers in cell and developmental biology · 2026Review
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Exploring the Potential of Novel Animal-Origin Probiotics as Key Players in One Health: Opportunities and Challenges.International journal of molecular sciences · 2025Review
- Conjugated Linoleic Acid in Cancer Therapy.Current drug delivery · 2025Review
- Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy.Frontiers in immunology · 2024Review
- Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis.Bone research · 2023Review
- Article
- Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Conjugated linoleic acid modifies transcriptional cytokine profile and induces early specific secretory IgA response inIranian journal of basic medical sciences · 2022Article
- Effects of Probiotics at the Interface of Metabolism and Immunity to Prevent Colorectal Cancer-Associated Gut Inflammation: A Systematic Network and Meta-Analysis With Molecular Docking Studies.Frontiers in microbiology · 2022Article
- The role of the gut microbiota and probiotics associated with microbial metabolisms in cancer prevention and therapy.Frontiers in pharmacology · 2022Review
- Correction: Immunoregulatory Mechanisms Underlying Prevention of Colitis-Associated Colorectal Cancer by Probiotic Bacteria.PloS one · 2022Article
- The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections.Frontiers in microbiology · 2022Review
- Roles of the Polyphenol-Gut Microbiota Interaction in Alleviating Colitis and Preventing Colitis-Associated Colorectal Cancer.Advances in nutrition (Bethesda, Md.) · 2021Review
- Inhibitory Effects of Breast Milk-DerivedNutrients · 2021Article
- An Update on the Effects of Probiotics on Gastrointestinal Cancers.Frontiers in pharmacology · 2021Review
- The Role of Probiotics in Cancer Prevention.Cancers · 2020Review
- The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review.Nutrients · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) increases the risk of colorectal cancer. Probiotic bacteria produce immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-carcinogenic effects. This study aimed to investigate the cellular and molecular mechanisms underlying the efficacy of probiotic bacteria in mouse models of cancer. METHODOLOGY/PRINCIPAL
findingsThe immune modulatory mechanisms of VSL#3 probiotic bacteria and CLA were investigated in mouse models of inflammation-driven colorectal cancer. Colonic specimens were collected for histopathology, gene expression and flow cytometry analyses. Immune cell subsets in the mesenteric lymph nodes (MLN), spleen and colonic lamina propria lymphocytes (LPL) were phenotypically and functionally characterized. Mice treated with CLA or VSL#3 recovered faster from the acute inflammatory phase of disease and had lower disease severity in the chronic, tumor-bearing phase of disease. Adenoma and adenocarcinoma formation was also diminished by both treatments. VSL#3 increased the mRNA expression of TNF-α, angiostatin and PPAR γ whereas CLA decreased COX-2 levels. Moreover, VSL#3-treated mice had increased IL-17 expression in MLN CD4+ T cells and accumulation of Treg LPL and memory CD4+ T cells. CONCLUSIONS/SIGNIFICANCE: Both CLA and VSL#3 suppressed colon carcinogenesis, although VSL#3 showed greater anti-carcinogenic and anti-inflammatory activities than CLA. Mechanistically, CLA modulated expression of COX-2 levels in the colonic mucosa, whereas VSL#3 targeted regulatory mucosal CD4+ T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.